CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ:HLCS) today announced that a leading U.S. cancer research center has placed an order for a Helicos™ Genetic Analysis System for use in a cutting-edge research program involving cancer stem cell biology. The Helicos Genetic Analysis System was chosen because of its unique capability of true direct DNA measurement which provides the most unbiased view of DNA and RNA critical for stem cell research.
